Wu GS. Updates on antibody-mediated rejection in intestinal transplantation. World J Transplant 2016; 6(3): 564-572 [PMID: 27683635 DOI: 10.5500/wjt.v6.i3.564]
Corresponding Author of This Article
Guo-Sheng Wu, MD, PhD, Division of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, #127 Changle West Rd, Xi’an 710032, Shannxi Province, China. guosheng_w@yahoo.com
Research Domain of This Article
Transplantation
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Transplant. Sep 24, 2016; 6(3): 564-572 Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.564
Updates on antibody-mediated rejection in intestinal transplantation
Guo-Sheng Wu
Guo-Sheng Wu, Division of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, Xi’an 710032, Shannxi Province, China
Author contributions: Wu GS solely contributed to this paper.
Supported by The grant from the National Natural Science Foundation of China, No. 81570588.
Conflict-of-interest statement: The author declares no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Guo-Sheng Wu, MD, PhD, Division of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, #127 Changle West Rd, Xi’an 710032, Shannxi Province, China. guosheng_w@yahoo.com
Telephone: +86-29-84771508 Fax: +86-29-82539041
Received: April 29, 2016 Peer-review started: May 3, 2016 First decision: June 17, 2016 Revised: July 30, 2016 Accepted: August 17, 2016 Article in press: August 18, 2016 Published online: September 24, 2016
Core Tip
Core tip: Antibody-mediated rejection (ABMR) has increasingly surfaced as an important cause of allograft loss after intestinal transplantation. The presence of donor-specific antibodies (DSAs) should alert the clinician of the increased risk of ABMR. The avoidance of a known donor-specific antibody target at the time of transplant remains a primary preventive strategy. The development of newly-formed DSAs usually portends a poor prognosis with an increased risk of refractory acute rejection, chronic rejection, and allograft loss. The better understanding of mechanisms of antibody-mediated graft injury, establishment of the diagnostic criteria, and optimal management of these antibodies may improve clinical outcomes of intestine transplants.
